{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:58:05Z","timestamp":1791140285544,"version":"4.1.0"},"reference-count":114,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease (AD) or other causes of cognitive decline. Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice. This review examines the progress made in overcoming these obstacles and describes the concurrent evolution of the diagnostic landscape. Advances in quantification methods have further strengthened the traditional visual assessment approach. Over the past decade, compelling evidence has emerged, demonstrating that amyloid PET has a strong impact on AD diagnosis, management, and outcomes across diverse clinical scenarios, even in the absence of amyloid-targeted therapies. Amyloid PET imaging has become essential in clinical trials and the application of new AD therapeutics, particularly for confirming eligibility criteria (i.e., the presence of amyloid plaques) and monitoring biological responses to amyloid-lowering therapies. Since its approval, FBB PET has transitioned from a purely diagnostic tool aimed primarily at excluding amyloid pathology to a critical component in AD drug development, and today, it is essential in the diagnostic workup and therapy management of approved AD treatments.<\/jats:p>","DOI":"10.3390\/ph17121648","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:16:14Z","timestamp":1733724974000},"page":"1648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET\u2014A Decade of Post-Authorization Insights"],"prefix":"10.3390","volume":"17","author":[{"given":"Aleksandar","family":"Jovalekic","sequence":"first","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Bullich","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Ro\u00e9-Vellv\u00e9","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Domingues","family":"Kolinger","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorelei R.","family":"Howard","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Elsholz","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Lagos-Quintana","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Blanco-Rodriguez","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Gismondi","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8398-880X","authenticated-orcid":false,"given":"Audrey","family":"Perrotin","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Chapleau","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging Inc., 75 State Street, Floor 1, Boston, MA 02109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keegan","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging Inc., 75 State Street, Floor 1, Boston, MA 02109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-9303","authenticated-orcid":false,"given":"Andre","family":"Mueller","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-8201","authenticated-orcid":false,"given":"Norman","family":"Koglin","sequence":"additional","affiliation":[{"name":"Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40120-022-00335-x","article-title":"The Humanistic and Economic Burden of Alzheimer\u2019s Disease","volume":"11","author":"Byrnes","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2023). Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_4","unstructured":"(2024, October 21). Rethinking Alzheimer\u2019s disease\u2014Detection and Diagnosis\u2014White Paper. Available online: https:\/\/www.braincouncil.eu\/wp-content\/uploads\/2023\/04\/RETHINK-AlzheimerDisease-Report_DEF3_HD_rvb_03042023.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100093","DOI":"10.1016\/j.nbas.2023.100093","article-title":"Rethinking the detection and diagnosis of Alzheimer\u2019s disease: Outcomes of a European Brain Council project","volume":"4","author":"Dumas","year":"2023","journal-title":"Aging Brain"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1002\/alz.14317","article-title":"Amyloid PET detects the deposition of brain Abeta earlier than CSF fluid biomarkers","volume":"20","author":"Lowe","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.115.161927","article-title":"Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study","volume":"57","author":"Seibyl","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_13","unstructured":"Jovalekic, A., Bullich, S., Roe-Vellve, N., Elsholz, F., Lagos-Quintana, M., Gismondi, R., Perrotin, A., Mueller, A., Stephens, A.W., and Koglin, N. (2024, January 5\u20139). Experiences from clinical research and routine use with Neuraceq Amyloid PET during 10 years post-authorisation\u2014Primed for the future. Proceedings of the ADPD, Lisbon, Portugal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","article-title":"Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods","volume":"50","author":"Jovalekic","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Collij, L.E., Bollack, A., La Joie, R., Shekari, M., Bullich, S., Roe-Vellve, N., Koglin, N., Jovalekic, A., Garcia, D.V., and Drzezga, A. (Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc., 2024). Centiloid recommendations for clinical context-of-use from the AMYPAD consortium, Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc., ahead of print.","DOI":"10.1002\/alz.14336"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","article-title":"Added value of (18)F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study","volume":"14","author":"Ceccaldi","year":"2018","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of Amyloid Positron Emission Tomography with Subsequent Change in Clinical Management Among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of Amyloid Positron Emission Tomography with Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project","volume":"75","author":"Pelkmans","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","article-title":"A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer\u2019s Disease","volume":"63","author":"Fantoni","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer\u2019s Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer\u2019s disease: Revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer\u2019s disease: A new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"ref_28","first-page":"426","article-title":"Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer\u2019s Disease: An Overview of Tests for Clinical Practice in the United States and Europe","volume":"10","author":"Iaccarino","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease","volume":"5","author":"Scholl","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment with Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_36","unstructured":"Battioui, C., Gueorguieva, I., Lu, M., Collins, E.C., Sims, J., and Shcherbinin, S. (2024, January 5\u20139). Baseline characteristics associated with achieving rapid amyloid plaque clearance following donanemab treatment. Proceedings of the ADPD, Lisbon, Portugal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1021\/jm050166g","article-title":"F-18 Stilbenes As PET Imaging Agents For Detecting?\u2014Amyloid Plaques in the Brain","volume":"48","author":"Zhang","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_39","unstructured":"Life Molecular Imaging (2024, October 21). Neuraceq US Prescribing Information. Available online: https:\/\/neuraceq.com\/wp-content\/uploads\/USPI-DOC-1118-v6.0.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-015-0258-7","article-title":"[18F]Florbetaben: A review in beta-amyloid PET imaging in cognitive impairment","volume":"29","author":"Syed","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","article-title":"Abeta imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: A prospective outcome study","volume":"86","author":"Ong","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","unstructured":"Life Molecular Imaging (2024, October 21). Neuraceq Summary of Product Characteristics (EU). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neuraceq-epar-product-information_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: A multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin. Transl. Imaging"},{"key":"ref_45","first-page":"1822","article-title":"Performance of 18F-Florbetaben PET Image Reading Training in Japanese language","volume":"57","author":"Bullich","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: A state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","article-title":"Early detection of amyloid load using (18)F-florbetaben PET","volume":"13","author":"Bullich","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.116.187351","article-title":"Optimal Reference Region to Measure Longitudinal Amyloid-beta Change with (18)F-Florbetaben PET","volume":"58","author":"Bullich","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1002\/alz.13883","article-title":"Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology","volume":"20","author":"Shekari","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","article-title":"Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: The CapAIBL, VIZCalc, and Amyquant methods","volume":"38","author":"Shang","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"ref_52","unstructured":"EMA (2024, October 21). Qualification Opinion for Centiloid Measure of Amyloid PET to Quantify Brain Amyloid Deposition. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/alz.12886","article-title":"Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project","volume":"19","author":"Collij","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","article-title":"A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images","volume":"48","author":"Bucci","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","unstructured":"Balhorn, W., Krawiec, K., Cole, N., and Nelson, A. (2024, October 21). Standardizing Quantification of Amyloid PET Using the Centiloid Scale. Available online: https:\/\/go.mimsoftware.com\/hubfs\/Downloadable%20Content\/Nuclear%20Medicine\/Standardizing_Quantification_of_Amyloid_PET_using_the_Centiloid_Scale-20220321.pdf."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e066217","DOI":"10.1002\/alz.066217","article-title":"Quantitative analysis of 6,150 real-world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia\u2013Evidence for Amyloid Scanning (IDEAS) study","volume":"18","author":"Zeltzer","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"118775","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"NeuroImage"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Collij, L.E., Bischof, G.N., Altomare, D., Bader, I., Battle, M., Vallez Garcia, D., Lopes Alves, I., Wolz, R., Gismondi, R., and Stephens, A. (J. Nucl. Med., 2024). Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study, J. Nucl. Med., accepted.","DOI":"10.2967\/jnumed.124.268119"},{"key":"ref_59","unstructured":"Life Molecular Imaging (2024, October 21). Neuraceq Summary of Product Charateristics (UK). Available online: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/85b0002715878eae8daaa3c4e8829d2f5a81c4e1."},{"key":"ref_60","first-page":"e662","article-title":"Association of \u03b2-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals","volume":"96","author":"Truong","year":"2021","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2967\/jnumed.123.265766","article-title":"Quantitative Brain Amyloid PET","volume":"65","author":"Jagust","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_63","first-page":"e-1","article-title":"Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_64","unstructured":"CMS (2024, October 21). Final Decision Memorandum for: CAG-00431N\u2014Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease, Available online: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=265."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e078912","DOI":"10.1002\/alz.078912","article-title":"Updated Appropriate Use Criteria for Amyloid and Tau PET in Alzheimer\u2019s Disease","volume":"19","author":"Rabinovici","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","article-title":"Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial","volume":"80","author":"Altomare","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical Use and Utility of Amyloid Imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000492151","article-title":"A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice","volume":"46","author":"Kim","year":"2018","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-180239","article-title":"Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis","volume":"64","author":"Shea","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jalz.2019.07.003","article-title":"Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project","volume":"15","author":"Ossenkoppele","year":"2019","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/alz.12846","article-title":"A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting","volume":"19","author":"Broulikova","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3233\/JAD-181146","article-title":"Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer\u2019s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins","volume":"68","author":"Manca","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-019-04466-6","article-title":"Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer\u2019s disease","volume":"47","author":"Ramusino","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","article-title":"Diagnostic impact of [18F]flutemetamol PET in early-onset dementia","volume":"9","author":"Zwan","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","article-title":"Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients with Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET with [18F]-Florbetapir (INDIA-FBP) Study","volume":"73","author":"Boccardi","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_78","first-page":"100","article-title":"FACEHBI: A Prospective Study of Risk Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study Rationale and Research Protocols","volume":"4","author":"Sanabria","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_79","unstructured":"Kolinger, G., Marqui\u00e9, M., Sotolongo-Grau, O., Ro\u00e9-Vellv\u00e9, N., P\u00e9rez-Mart\u00ednez, E., Koglin, N., Stephens, A., Tartari, J., Sanabria, A., and Garc\u00eda-S\u00e1nchez, A. (2024, January 19\u201323). Quantification of baseline amyloid load in individuals with subjective cognitive decline can identify future risk of amyloid accumulation. Proceedings of the EANM, Hamburg, Germany."},{"key":"ref_80","first-page":"S98","article-title":"Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer\u2019s Disease Study (LEADS)","volume":"19","author":"Cho","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3233\/JAD-210543","article-title":"Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study","volume":"86","author":"Zhang","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref_82","first-page":"e12267","article-title":"Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study","volume":"14","author":"Zhang","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/alz.12647","article-title":"Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: Important considerations for clinical trials and practice","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"O\u2019Bryant, S.E., Petersen, M., Hall, J., and Johnson, L. (2022). APOEepsilon4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.834685"},{"key":"ref_85","first-page":"e12518","article-title":"Top Alzheimer\u2019s disease risk allele frequencies differ in HABS-HD Mexican- versus Non-Hispanic White Americans","volume":"15","author":"Housini","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and Ethnic Differences in Amyloid PET Positivity in Individuals with Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_87","unstructured":"EISAI (2024, November 30). LEQEMBI\u00ae (lecanemab-irmb) USPI, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761269s008lbl.pdf."},{"key":"ref_88","unstructured":"EISAI (2024, October 21). LEQEMBI\u2014Summary of Product Characteristics\u2014UK. Available online: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/8c386e8ff40d92a383d0bc4efb2ce7325b61f88b."},{"key":"ref_89","unstructured":"Lilly (2024, October 21). KISUNLA (donanemab-azbt)\u2014USPI. Available online: https:\/\/pi.lilly.com\/us\/kisunla-uspi.pdf?s=pi."},{"key":"ref_90","unstructured":"CMS (2024, October 21). National Coverage Determination Reconsideration for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease\u2014CAG-00431R, Available online: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&ncaid=308."},{"key":"ref_91","first-page":"303","article-title":"Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus","volume":"34","author":"Arbizu","year":"2015","journal-title":"Rev. Esp. Med. Nucl. E Imagen Mol."},{"key":"ref_92","unstructured":"PRESTAZIONI di ASSISTENZA SPECIALISTICA AMBULATORIALE (ALLEGATO 4 DPCM LEA 12.01.2017)."},{"key":"ref_93","unstructured":"HAS (2024, October 21). NEURACEQ (florbetaben 18F)\u2014Alzheimer\u2019s Disease. Available online: https:\/\/www.has-sante.fr\/jcms\/p_3427910\/en\/."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e12383","DOI":"10.1002\/trc2.12383","article-title":"Patient-related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE","volume":"9","author":"Teipel","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/alz.13761","article-title":"Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study","volume":"20","author":"Bollack","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_97","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e078175","DOI":"10.1002\/alz.078175","article-title":"Amyloid re-accumulation after donanemab treatment: Summary from 3 interventional trials","volume":"19","author":"Shcherbinin","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.0000000000207438","article-title":"Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?","volume":"101","author":"Knopman","year":"2023","journal-title":"Neurology"},{"key":"ref_101","unstructured":"Eli Lilly (2024, October 21). June 10, 2024: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting\u2014Eli Lilly presentation, Available online: https:\/\/www.fda.gov\/media\/179240\/download."},{"key":"ref_102","unstructured":"FDA (2024, October 21). FDA Issues Guidance Regarding Drug Dvelopment for Early Alzheimer\u2019s Disease, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-guidance-regarding-drug-development-early-alzheimers-disease."},{"key":"ref_103","unstructured":"FDA (2024, October 21). FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Pascoal, T.A., Aguzzoli, C.S., Lussier, F.Z., Crivelli, L., Suemoto, C.K., Fortea, J., Rosa-Neto, P., Zimmer, E.R., Ferreira, P.C.L., and Bellaver, B. (2024). Insights into the use of biomarkers in clinical trials in Alzheimer\u2019s disease. eBioMedicine, 108.","DOI":"10.1016\/j.ebiom.2024.105322"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer\u2019s disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_106","unstructured":"Kulic, L. (2024, January 5\u20139). Rapid dose-dependent amyloid plaque depletion with trontinemab, a novel BrainshuttleTM antibody in development for the treatment of Alzheimer\u2019s disease. Proceedings of the ADPD, Lisbon, Portugal."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Pizzo, M.E., Plowey, E.D., Khoury, N., Kwan, W., Abettan, J., DeVos, S.L., Discenza, C.B., Earr, T., Joy, D., and Lye-Barthel, M. (2024). Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA. bioRxiv.","DOI":"10.1101\/2024.07.26.604664"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","article-title":"Brain Shuttle Antibody for Alzheimer\u2019s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode","volume":"22","author":"Weber","year":"2018","journal-title":"Cell Rep."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Karlawish, J., and Grill, J.D. (2024). Alzheimer\u2019s disease biomarkers and the tyranny of treatment. eBioMedicine, 108.","DOI":"10.1016\/j.ebiom.2024.105291"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Visser, L.N.C., van Maurik, I.S., Bouwman, F.H., Staekenborg, S., Vreeswijk, R., Hempenius, L., de Beer, M.H., Roks, G., Boelaarts, L., and Kleijer, M. (2020). Clinicians\u2019 communication with patients receiving a MCI diagnosis: The ABIDE project. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227282"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jval.2015.10.011","article-title":"Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer\u2019s Disease","volume":"19","author":"Muhlbacher","year":"2016","journal-title":"Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"ref_113","first-page":"111","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3233\/JAD-190836","article-title":"Why Is Amyloid-\u03b2 PET Requested After Performing CSF Biomarkers?","volume":"73","author":"Reimand","year":"2020","journal-title":"J. Alzheimers Dis."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:49:31Z","timestamp":1760114971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":114,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121648"],"URL":"https:\/\/doi.org\/10.3390\/ph17121648","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}